Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02964572
Other study ID # 4-2016-0795
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2016
Est. completion date July 2017

Study information

Verified date August 2020
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

- Single-center, prospective, active-controlled, open, randomized, 2 arm parallel, interventional, exploratory pilot

- Type 2 diabetic patients with high cardiovascular risks who have inadequate glycaemic control with metformin-based oral hypoglycemic agents will be prescribed glimepiride (comparison group) or empagliflozin (study group) for 60 days (plus or minus 32 days) as add-on therapy

- Changes in IL-1beta secretion, serum beta-hydroxybutyrate concentration, and NLRP3 inflammasome activity from baseline to final timepoint will be assessed.


Description:

First among cardiovascular (CV) end point trials of glucose-lowering agents, the EMPA-REG OUTCOME trial-using 10 or 25 mg/day SGLT2 inhibitor empagliflozin against placebo in 7,020 patients with T2DM who were at increased CV risk-reported a 14% reduction in major CV events and marked relative risk reductions in CV mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) over a median time period of 2.6 years. Though these results have raised the possibility that mechanisms other than those observed in the trial-modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level-may be at play, it's not clearly known yet.

The inflammatory nature of atherosclerosis is well established. We hypothesized that empagliflozin might have an inhibitory effect on inflammasome activity in macrophages, thus contribute to cardioprotective effects in diabetes.

- Single-center, prospective, active-controlled, open, randomized, 2 arm parallel, interventional, exploratory pilot

- Type 2 diabetic patients with high cardiovascular risks who have inadequate glycaemic control with metformin-based oral hypoglycemic agents will be prescribed glimepiride (comparison group) or empagliflozin (study group) for 60 days (plus or minus 32 days) as add-on therapy

- Changes in IL-1beta secretion, serum beta-hydroxybutyrate concentration, and NLRP3 inflammasome activity from baseline to final timepoint will be assessed

- Healthy volunteers : effect of 3 day-ketogenic diet on changes in cytokines, metabolites (IL-1beta, beta-hydroxybutyrate , etc) and inflammasome activity in macrophages


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date July 2017
Est. primary completion date July 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 85 Years
Eligibility Inclusion Criteria:

- Age =19 years

- inadequate glycaemic control : HbA1c =6.5% or fasting glucose >120 mg/dl or random glucose >180 mg/dl

- High risk of cardiovascular events defined as the presence of =1 of the following:

1. History of myocardial infarction

2. Evidence of multi-vessel coronary artery disease

3. Evidence of single-vessel coronary artery disease with a positive non-invasive stress test for ischemia or history of hospitalization for unstable angina

4. History of stroke

5. Evidence of occlusive peripheral artery disease

6. Evidence of carotid atherosclerosis

7. Metabolic syndrome

- Healthy volunteers

Exclusion Criteria:

- Type 1 diabetes

- Organ transplantation

- Pregnant women

- eGFR <45

- Cortisol or growth hormone deficiency, pituitary diseases

- Gastric surgery

- Hematologic disorders

- Active cancers

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Glimepiride
In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.
Empagliflozin
Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.

Locations

Country Name City State
Korea, Republic of Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary changes in the secretion of IL-1 beta from peripheral blood mononuclear cells The effect of empagliflozin on the secretion of IL-1beta from peripheral blood mononuclear cells Day 60
Secondary Changes in the secretion of TNF-alpha from peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in serum concentrations of beta-hydroxybutyrate, before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in body weight (kg), before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in serum concentrations of insulin (µU/mL), before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in serum concentrations of glucagon (pg/mL), before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in serum concentrations of free fatty acid (µEq/L), before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in serum glycated albumin (%), before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in serum concentrations of glucose (mg/dL), before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in serum concentrations of uric acid (mg/dL), before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in serum concentrations of liver enzymes (aspartate aminotransferase and alanine aminotransferase (IU/L)), before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in serum lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol (mg/dL)), before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in serum concentrations of creatinine (mg/dL), before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in spot urine concentrations of glucose (mg/dL) and creatinine (mg/dL) (those will be combined to report spot urine glucose-to-creatinine ratio in mg/mg), before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in mRNA expression level (PCR, fold) of IL-1beta, TNF-alpha, and NLRP3 in peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
Secondary Changes in protein expression pattern (western blot, relative to control) of IL-1beta, TNF-alpha, and NLRP3 in peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride Day 60 plus or minus 32 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03655535 - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes Phase 2
Completed NCT03256747 - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes N/A
Withdrawn NCT03675074 - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes N/A
Completed NCT05343767 - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus N/A
Withdrawn NCT03190798 - Effects of Canagliflozin on Intravascular Volume and Hemodynamics Phase 4
Withdrawn NCT03437330 - Empagliflozin Effect on Glucose Toxicity Phase 4
Withdrawn NCT03008395 - Empowerment, Motivation and Medical Adherence (EMMA). N/A
Not yet recruiting NCT05539066 - AI Health Assistant and Type 2 Diabetes N/A
Completed NCT03682445 - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus N/A
Not yet recruiting NCT03239119 - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus Phase 3
Completed NCT03259789 - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Phase 3
Recruiting NCT03506230 - Financial Incentives for Low Socioeconomic Diabetic Patients N/A
Completed NCT03072407 - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM Phase 1
Completed NCT05668442 - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed NCT02956044 - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Phase 1
Completed NCT02628392 - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) N/A
Completed NCT03104738 - Basal Insulin Strategies Before Surgery N/A